Pemirolast potassium CAS NO.100299-08-9
Active Pharmaceutical Ingredients 2025-03-03
Catalog ID80017373
CAS NO.100299-08-9
Purity 99%
MDL NumberMFCD01690051
Molecular Formula C10H7KN6O
Molecular Weight 267.3084
Melting point: >300°C
| Aspect | Details |
|---|---|
| Mechanism of Action | Pemirolast potassium is a mast cell stabilizer that inhibits the release of inflammatory mediators (e.g., histamine, leukotriene C4, D4, E4) from human mast cells. It also acts as a histamine H1 antagonist, blocking the action of histamine on effector cells. |
| Indications | – Prophylactic treatment of itching associated with allergic conjunctivitis.<br>- Used in ophthalmic anti-allergic formulations. |
| Pharmacokinetics | – Absorption: Detectable plasma concentrations after topical ocular administration.<br>- Elimination: Excreted primarily via urine; about 10-15% of the dose is excreted unchanged.<br>- Half-Life: 4.5 hours (ophthalmic). |
| Storage Conditions | Stable under ambient conditions in sealed containers; hygroscopic. Store below 30°C. |
| Physical Properties | – Appearance: White to off-white crystalline powder.<br>- Solubility: Freely soluble in water (>50 mg/mL), sparingly soluble in ethanol. |
| Dosage Forms | – Ophthalmic solution.<br>- Tablets. |
| Adverse Effects | – Common: Eye irritation, headache, dry eye.<br>- Serious: Hypersensitivity reactions. |
| Special Considerations | – Use with caution in pregnant or breastfeeding women due to potential risks to the fetus or infant.<br>- Monitor for signs of hypersensitivity. |
| Toxicity | – Not mutagenic or clastogenic in vitro or in vivo.<br>- Increased incidence of developmental abnormalities in animal studies at high doses. |
Disclaimer: The above content is for reference and communication only among industry insiders, and does not guarantee its accuracy or completeness. According to relevant laws and regulations and the regulations of this website, units or individuals who purchase related items should obtain valid qualifications and qualification conditions.
